You are here

Shire to buy rare-disease drugmaker NPS Pharmaceuticals for US$5.2b

Deal comes before NPS learns whether its Natpara medicine to treat hypoparathyroidism wins approval from the US FDA

NPS has "a rare-disease focus and ... it builds on our strong expertise in gastrointestinal diseases", says Mr Ornskov.


SHIRE plc, the drugmaker seeking to boost growth after its proposed sale to AbbVie Inc collapsed, agreed to buy NPS Pharmaceuticals Inc for about US$5.2 billion to add medicines used to treat rare diseases.

Shire will pay US$46 a share in cash, the Dublin-based company said...

Market voices on: